GlassScriptPhysician profile
Alexander Feldman
NPI 1134179914
$27,580.67
in general payments reported to CMS, 2019-2025
77 companies · $4,760 in 2025
The $4,760 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,691 · 2020: $2,058 · 2021: $3,726 · 2022: $4,413 · 2023: $5,054 · 2024: $4,879 · 2025: $4,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $67.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,625.21 |
| Education | $67.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,653.92 | 2020-2025 | |
| Ucb, INC. | $2,029.10 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Pfizer INC. | $1,647.40 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $1,330.53 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $1,053.71 | 2019-2025 | Ultomiris, Soliris |
| Abbott Laboratories | $953.21 | 2021-2025 | Infinity |
| Emd Serono, INC. | $900.16 | 2019-2025 | Mavenclad |
| Mallinckrodt Hospital Products INC. | $899.74 | 2020-2025 | Acthar |
| Lilly USA, LLC | $844.44 | 2019-2025 | Kisunla, Amyvid, Reyvow |
| Sk Life Science, INC. | $809.91 | 2020-2025 | Xcopri |
| Allergan, INC. | $769.21 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $744.21 | 2021-2025 | Xeomin, Inbrija |
| Teva Pharmaceuticals USA, INC. | $718.32 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Eisai INC. | $710.15 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $631.94 | 2019-2024 | Rytary |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $627.69 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Mdd US Operations, LLC | $598.21 | 2019-2022 | |
| Amgen INC. | $501.64 | 2019-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $499.32 | 2019-2025 | Nuplazid, Daybue |
| Neurelis, INC. | $424.24 | 2022-2025 | Valtoco |
| Genzyme Corporation | $401.89 | 2019-2025 | |
| Harmony Biosciences LLC | $397.89 | 2020-2025 | Wakix |
| Argenx US, INC. | $386.49 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biohaven Pharmaceuticals, INC. | $369.87 | 2020-2021 | |
| Tg Therapeutics, INC. | $366.69 | 2023-2025 | |
| Lundbeck LLC | $364.72 | 2019-2025 | Vyepti |
| Jazz Pharmaceuticals INC. | $361.86 | 2020-2024 | Epidiolex |
| Genentech USA, INC. | $319.96 | 2021-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Supernus Pharmaceuticals, INC. | $311.49 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $295.35 | 2019 | |
| Alnylam Pharmaceuticals INC. | $259.77 | 2022-2023 | Onpattro |
| Neurocrine Biosciences, INC. | $251.06 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $223.54 | 2024-2025 | Ponvory |
| Axsome Therapeutics, INC. | $217.75 | 2022-2025 | Symbravo, Sunosi |
| Biohaven Pharmaceutical Holding Company LTD. | $212.44 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $210.38 | 2019-2025 | Firdapse |
| Celgene Corporation | $196.88 | 2021-2025 | Zeposia |
| Merz North America, INC. | $170.13 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $132.03 | 2023-2025 | Rexulti |
| Kyowa Kirin, INC. | $120.73 | 2020-2024 | Nourianz |
| Grifols USA, LLC | $119.94 | 2021-2025 | Gamunex-C |
| Boston Scientific Corporation | $115.16 | 2023-2025 | Vercise, Wavewriter Alpha Prime 16 |
| Tanabe Pharma America, INC. | $108.73 | 2020-2023 | |
| Octapharma USA, INC. | $103.16 | 2023 | Panzyga |
| Ani Pharmaceuticals, INC. | $84.68 | 2025 | Purified Cortrophin Gel |
| Bausch Health US, LLC | $80.81 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $80.12 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $78.57 | 2023-2025 | Wainua |
| Banner Life Sciences, LLC | $70.39 | 2021-2024 | |
| Insightec,INC | $64.57 | 2025 | Exablate |
| Takeda Pharmaceuticals U.S.A., INC. | $62.19 | 2024 | Hyqvia |
| Springworks Therapeutics, INC. | $57.32 | 2025 | Gomekli |
| Medtronic USA, INC. | $47.32 | 2019 | |
| Amylyx Pharmaceuticals, INC. | $45.40 | 2023 | Relyvrio |
| Janssen Biotech, INC. | $44.53 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $42.76 | 2020-2021 | |
| Medtronic, INC. | $36.68 | 2021-2024 | Percept PC Brainsense |
| Janssen Pharmaceuticals, INC | $36.59 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $33.21 | 2022 | |
| Almatica Pharma LLC | $31.34 | 2021 | |
| Nevro Corp. | $27.47 | 2023 | Senza |
| Nobelpharma America, LLC | $26.60 | 2024 | |
| Ns Pharma, INC. | $24.76 | 2023 | Viltepso |
| C2n Diagnostics, LLC | $24.27 | 2025 | Precivityad2 |
| Livanova USA, INC. | $21.64 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Vertical Pharmaceuticals, LLC | $21.59 | 2019 | |
| Impel Pharmaceuticals INC. | $21.44 | 2022 | |
| Csl Behring | $21.27 | 2020 | |
| Sumitomo Pharma America, INC. | $20.63 | 2024 | Aptiom |
| Alfasigma USA, INC. | $20.09 | 2021 | |
| Assertio Therapeutics, INC. | $19.83 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $19.58 | 2022 | |
| Acorda Therapeutics, INC | $17.66 | 2019 | |
| Avion Pharmaceuticals | $14.85 | 2023 | Dhivy |
| Ge Healthcare | $14.23 | 2023 | |
| Travere Therapeutics, INC. | $3.32 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.